ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs

Bibliography

• Buyse M, Radeva G, Bado A, Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 2005;69:1745-54
   PubMed Web of Science ®Google Scholar
• Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol 2001;13:463-9
   PubMed Web of Science ®Google Scholar
• Dombrowski SM, Desai SY, Marroni M, Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-6
   PubMed Web of Science ®Google Scholar
• Vogelgesang S, Cascorbi I, Schroeder E, Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002;12:535-41
   PubMedGoogle Scholar
• Scherrmann JM. Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert Opin Drug Metab Toxicol 2005;1:233-46
   PubMedGoogle Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O'Brien JP, Casals D, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Golden PL, Kang YS, Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 1997;68:1278-85
   PubMed Web of Science ®Google Scholar
• Rao VV, Dahlheimer JL, Bardgett ME, Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999;96:3900-5
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer 1991;27:1639-42
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Greenblatt DJ. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica 2004;34:133-50
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Fricker G, Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004;66:413-9
   PubMed Web of Science ®Google Scholar
• Gant TW, O'Connor CK, Corbitt R, In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995;133:269-76
   PubMed Web of Science ®Google Scholar
• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-7
   PubMed Web of Science ®Google Scholar
• Langford D, Grigorian A, Hurford R, Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004;63:1038-47
   PubMed Web of Science ®Google Scholar
• Lam FC, Liu R, Lu P, beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 2001;76:1121-8
   PubMed Web of Science ®Google Scholar
• Vogelgesang S, Warzok RW, Cascorbi I, The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004;1:121-5
   PubMed Web of Science ®Google Scholar
• Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006;116:1744-54
   PubMed Web of Science ®Google Scholar
• Gerlach M, Riederer P, Przuntek H, MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 1991;208:273-86
   PubMed Web of Science ®Google Scholar
• Staal RG, Yang JM, Hait WN, Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 2001;910:116-25
   PubMed Web of Science ®Google Scholar
• Firestone JA, Smith-Weller T, Franklin G, Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 2005;62:91-5
   PubMed Web of Science ®Google Scholar
• Hertzman C, Wiens M, Bowering D, Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Ind Med 1990;17:349-55
   PubMed Web of Science ®Google Scholar
• Liou HH, Tsai MC, Chen CJ, Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583-8
   PubMed Web of Science ®Google Scholar
• Bove J, Prou D, Perier C, Toxin-induced models of Parkinson's disease. NeuroRx 2005;2:484-94
   PubMedGoogle Scholar
• Betarbet R, Sherer TB, MacKenzie G, Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6
   PubMed Web of Science ®Google Scholar
• Lecoeur S, Videmann B, Mazallon M. Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. Toxicol Lett 2006;161:200-9
   PubMed Web of Science ®Google Scholar
• Shabbir A, DiStasio S, Zhao J, Differential effects of the organochlorine pesticide DDT and its metabolite p,p'-DDE on p-glycoprotein activity and expression. Toxicol Appl Pharmacol 2005;203:91-8
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ, Remiao F, Duarte JA, P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med 2006;41:1213-24
   PubMed Web of Science ®Google Scholar
• Caparros-Lefebvre D, Sergeant N, Lees A, Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002;125:801-11
   PubMed Web of Science ®Google Scholar
• Lannuzel A, Michel PP, Caparros-Lefebvre D, Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. Mov Disord 2002;17:84-90
   PubMed Web of Science ®Google Scholar
• Motoyama T, Yabunaka H, Miyoshi H. Essential structural factors of acetogenins, potent inhibitors of mitochondrial complex I. Bioorg Med Chem Lett 2002;12:2089-92
   PubMed Web of Science ®Google Scholar
• Lannuzel A, Michel PP, Hoglinger GU, The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 2003;121:287-96
   PubMed Web of Science ®Google Scholar
• Champy P, Hoglinger GU, Feger J, Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 2004;88:63-9
   PubMed Web of Science ®Google Scholar
• You M, Wickramaratne DB, Silva GL, (-)-Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. J Nat Prod 1995;58:598-604
   PubMed Web of Science ®Google Scholar
• Oberlies NH, Croy VL, Harrison ML, The Annonaceous acetogenin bullatacin is cytotoxic against multidrug-resistant human mammary adenocarcinoma cells. Cancer Lett 1997;115:73-9
   PubMed Web of Science ®Google Scholar
• Fu LW, Pan QC, Liang YJ, Circumvention of tumor multidrug resistance by a new annonaceous acetogenin: atemoyacin-B. Zhongguo Yao Li Xue Bao 1999;20:435-9
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8
   PubMed Web of Science ®Google Scholar
• Johne A, Kopke K, Gerloff T, Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002;72:584-94
   PubMed Web of Science ®Google Scholar
• Verstuyft C, Schwab M, Schaeffeler E, Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003;58:809-12
   PubMed Web of Science ®Google Scholar
• Brunner M, Langer O, Sunder-Plassmann R, Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 2005;78:182-90
   PubMed Web of Science ®Google Scholar
• Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006;109:137-61
   PubMed Web of Science ®Google Scholar
• Westerlund M, Belin AC, Anvret A, Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat Disord 2009;15:422-4
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Bialecka M, Mysliwiec K, Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003;13:259-63
   PubMedGoogle Scholar
• Furuno T, Landi MT, Ceroni M, Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002;12:529-34
   PubMedGoogle Scholar
• Lee CG, Tang K, Cheung YB, MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 2004;41:e60
   PubMed Web of Science ®Google Scholar
• Tan EK, Chan DK, Ng PW, Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 2005;62:460-4
   PubMed Web of Science ®Google Scholar
• Zschiedrich K, Konig IR, Bruggemann N, MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol 2009;256:115-20
   PubMed Web of Science ®Google Scholar
• de Vries HE, Kuiper J, de Boer AG, The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 1997;49:143-55
   PubMed Web of Science ®Google Scholar
• Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S49-58; discussion S58-60
   PubMedGoogle Scholar
• Thumwood CM, Hunt NH, Clark IA, Breakdown of the blood-brain barrier in murine cerebral malaria. Parasitology 1988;96(Pt 3):579-89
   PubMedGoogle Scholar
• McGeer PL, Itagaki S, Boyes BE, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-91
   PubMed Web of Science ®Google Scholar
• Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999;156:50-61
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Kondo T, Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995;9:87-92
   PubMedGoogle Scholar
• Nagatsu T, Mogi M, Ichinose H, Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000;60:277-90
   PubMedGoogle Scholar
• Fernandez C, Buyse M, German-Fattal M, Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci 2004;7:359-71
   PubMed Web of Science ®Google Scholar
• Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 2006;6:295-311
   PubMed Web of Science ®Google Scholar
• McRae MP, Brouwer KL, Kashuba AD. Cytokine regulation of P-glycoprotein. Drug Metab Rev 2003;35:19-33
   PubMed Web of Science ®Google Scholar
• Mandi Y, Ocsovszki I, Szabo D, Nitric oxide production and MDR expression by human brain endothelial cells. Anticancer Res 1998;18:3049-52
   PubMed Web of Science ®Google Scholar
• Theron D, Barraud de Lagerie S, Tardivel S, Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochem Pharmacol 2003;66:579-87
   PubMed Web of Science ®Google Scholar
• Walther W, Stein U, Pfeil D. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. Int J Cancer 1995;61:832-9
   PubMed Web of Science ®Google Scholar
• Zhao YL, Du J, Kanazawa H, Shiga-like toxin II modifies brain distribution of a P-glycoprotein substrate, doxorubicin, and P-glycoprotein expression in mice. Brain Res 2002;956:246-53
   PubMed Web of Science ®Google Scholar
• Combates NJ, Rzepka RW, Chen YN, NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem 1994;269:29715-9
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274:707-13
   PubMed Web of Science ®Google Scholar
• Westerlund M, Belin AC, Olson L, Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell Tissue Res 2008;334:179-85
   PubMed Web of Science ®Google Scholar
• Kortekaas R, Leenders KL, van Oostrom JC, Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57:176-9
   PubMed Web of Science ®Google Scholar
• Bartels AL, Willemsen AT, Kortekaas R, Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 2008;115:1001-9
   PubMed Web of Science ®Google Scholar
• Toornvliet R, van Berckel BN, Luurtsema G, Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006;79:540-8
   PubMed Web of Science ®Google Scholar
• Bartels AL, Kortekaas R, Bart J, Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 2008; In press
   PubMed Web of Science ®Google Scholar
• Homann CN, Wenzel K, Suppan K, Sleep attacks in patients taking dopamine agonists: review. BMJ 2002;324:1483-7
   PubMed Web of Science ®Google Scholar
• Furuya KN, Thottassery JV, Schuetz EG, Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway. J Biol Chem 1997;272:11518-25
   PubMed Web of Science ®Google Scholar
• Orlowski S, Valente D, Garrigos M, Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun 1998;244:481-8
   PubMed Web of Science ®Google Scholar
• Shiraki N, Okamura K, Tokunaga J, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells. Jpn J Cancer Res 2002;93:209-15
   PubMedGoogle Scholar
• Vautier S, Milane A, Fernandez C, Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model. Neurosci Lett 2008;442:19-23
   PubMed Web of Science ®Google Scholar
• Vautier S, Lacomblez L, Chacun H, Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur J Pharm Sci 2006;27:167-74
   PubMed Web of Science ®Google Scholar
• Soares-Da-Silva P, Serrao MP. Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells. J Pharmacol Exp Ther 2000;293:697-704
   PubMed Web of Science ®Google Scholar
• Soares-da-Silva P, Serrao MP, Vieira-Coelho MA, Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells. Br J Pharmacol 1998;123:13-22
   PubMed Web of Science ®Google Scholar
• Uhr M, Ebinger M, Rosenhagen MC, The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci Lett 2005;383:73-6
   PubMed Web of Science ®Google Scholar
• Guerin CJ, Nolan CC, Mavroudis G, The dynamics of blood-brain barrier breakdown in an experimental model of glial cell degeneration. Neuroscience 2001;103:873-83
   PubMed Web of Science ®Google Scholar
• Farkas E, De Jong GI, de Vos RA, Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol 2000;100:395-402
   PubMed Web of Science ®Google Scholar
• Rissling I, Geller F, Bandmann O, Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting “sleep attacks”. Mov Disord 2004;19:1279-84
   PubMed Web of Science ®Google Scholar
• Rissling I, Korner Y, Geller F, Preprohypocretin polymorphisms in Parkinson disease patients reporting “sleep attacks”. Sleep 2005;28:871-5
   PubMed Web of Science ®Google Scholar
• Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002;41:81-92
   PubMed Web of Science ®Google Scholar
• Xia CQ, Yang JJ, Gan LS. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 2005;1:595-611
   PubMed Web of Science ®Google Scholar
• Le Couteur DG, Davis MW, Webb M, P-glycoprotein, multidrug-resistance-associated protein and Parkinson's disease. Eur Neurol 2001;45:289-90
   PubMed Web of Science ®Google Scholar
• Tan EK, Drozdzik M, Bialecka M, Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci Lett 2004;372:240-4
   PubMed Web of Science ®Google Scholar
• Funke C, Soehn AS, Tomiuk J, Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J Neural Transm 2009;116:443-50
   PubMed Web of Science ®Google Scholar